|
|
4th International AIDS ConferenceStockholm, Sweden - June 12-16, 1988 |
Cite as: Int Conf AIDS. 1988 Jun 12-16;4:x (abstract no. xx)
| OPENING SESSION - KEYNOTE PRESENTATIONS | |
| Opening Ceremony Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. M1) Speakers include: His Majesty King Carl XVI Gustaf, Ingvar Carlsson, Prime Minister of Sweden; Bengt Samuelsson, President of the Karolinska Institute Abstract not available at time of printing. |
|
| K1 | THE EVOLUTION OF HIV's AND THEIR ROLE IN THE PATHOGENESIS OF AIDS Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. K1) Luc Montagnier HIV is the primary cause of AIDS and others related diseases. Two types have been so far characterized, each having a wide range of genetic variability and pathogenicity. HIV-1 which is associated with the main epidemic has no close relative in Primate retroviruses. HIV-2 is closely related by molecular and biochemical properties to the simian AIDS virus of Macaque, the latter being probably derived from a monkey retrovirus different from that of African Green monkey. |
| K2 | THE GLOBAL PICTURE OF AIDS Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. K2) Jonathan Mann HIV prevention relies upon informed individual behaviour (with a supportive social environment and relevant health and social support services) and ensuring the safety of specific practices in the health system. Throughout the world, national AIDS programmes are being rapidly developed; evaluation of these efforts will soon become possible. All sectors of the health system should contribute to the programme "Against AIDS - For Health". |
| K3 | THE BIOLOGY OF HIV-1 AND ITS RELATIONSHIP TO OTHER HUMAN RETROVIRUSES Int Conf AIDS. 1988 Jun 12-16;4:1.105 (abstract no. K3) Robert Gallo An international collaborative program (called HIVAC) to develop a vaccine against AIDS was initiated in 1984. Studies from members of this group have defined a neutralizing epitope (Putney et al.), and T cell epitopes (Berzofsky et al.). Other studies (Zagury et al.) have made the first attempts to define the immune response in man. |
| PLENARY SESSION I - Monday, June 13 | |
| PL1 | HUMAN IMMUNODEFICIENCY VIRUSES: NEUTRALIZATION AND RECEPTORS Int Conf AIDS. 1988 Jun 12-16;4:1.106 (abstract no. PL1) Robin A Weiss The envelope glycoproteins of HIV are important as targets for neutralizing antibodies and for the recognition of cell surface receptors. Serological studies of infected subjects and analysis of monoclonal antibodies to gp120 and gp4l indicate that both common and variable neutralization antigens exist in the HIV envelope. Some of these antigenic sites are becoming precisely defined and may be important in designing effective vaccines. |
| PL2 | THE EPIDEMIOLOGY OF HIV INFECTION AND AIDS IN THE UNITED STATES Int Conf AIDS. 1988 Jun 12-16;4:1.106 (abstract no. PL2) James W. Curran*, Harold W. Jaffe*, Ann M. Hardy*, W. Meade Morgan*, Richard M. Selik*, Timothy J. Dondero* By the end of 1987, nearly 50,000 cases of AIDS had been reported since 1981, 20,745 in the past year alone. Black and Hispanic adults and children have reported rates three to twelve times higher than whites. This can be largely. attributed to higher reported rates in Black and Hispanic IV drug abusers, their sex partners and infants. In 1986, reported AIDS deaths increased adult male and female mortality in the United States by an estimated 0.7 and 0.07% respectively with much greater increases in selected age groups or areas of the country. |
| PL3 | EPIDEMIOLOGY OF HIV INFECTION IN AFRICA Int Conf AIDS. 1988 Jun 12-16;4:1.106 (abstract no. PL3) Bosenge N'Galy Despite these marked regional differences in Africa, heterosexual transmission remains the dominant mode. Therefore, with local modifications, similar prevention and control strategies for limiting the spread of both HIV-1 and HIV-2 can be adopted in all African countries. |
| PL4 | AIDS AND HIV INFECTION IN EUROPE Int Conf AIDS. 1988 Jun 12-16;4:1.106 (abstract no. PL4) J.B. Brunet According to national estimates, the total population of HIV-infected persons in the 32 countries belonging to the WHO European region ranges between 280,000 and 800,000 individuals. Seroepidemiological surveys reveal wide variations in the rates of seropositivity in risk groups and in the general population as a whole both between and within countries. By December 1987, 10,215 AIDS cases had been reported in the region which represents a 124% increase in one year (5,666 newly reported cases). |
| PLENARY SESSION II - Tuesday, June 14 | |
| PL5 | REPLICATION AND PATHOGENESIS OF THE AIDS VIRUS Int Conf AIDS. 1988 Jun 12-16;4:1.107 (abstract no. PL5) William A. Haseltine HIV induces a slow progressive degenerative disease of the immune and central nervous systems. Initial viremia is followed by a long latent period that in turn is followed by re-emergence of the virus. A wide variety of cell types, all bearing CD4 surface protein can be infected by HIV but only CD4+ T cell lymphocytes are efficiently killed. A vigorous anti-viral humoral and detectable cell mediated immune responses are present in most infected people. |
| PL6 | THE ROLE OF MATHEMATICAL MODELS IN THE STUDY OF THE EPIDEMIOLOGY OF AIDS Int Conf AIDS. 1988 Jun 12-16;4:1.107 (abstract no. PL6) Roy M. Anderson, F.R.S. The paper examines the use of mathematical models in the study of HIV transmission and the epidemiology of AIDS. Attention is given to short and long term predictions, the estimation of epidemiological parameters such as the incubation period of the disease, the potential demographic impact of AIDS in the developing world andthe dynamics of viral replication within an infected person. |
| PL7 | IMMUNOPATHOLOGY OF HIV INFECTION Int Conf AIDS. 1988 Jun 12-16;4:1.107 (abstract no.PL7 ) Hans Wigzell The fact that HIV is using CD4, an essential molecule in many cellmediated immune reactions as its receptor puts extra strain on the immune system. The consequences as to cellular functions and specificity of anti-HIV antibodies being made seem manifold. Some may lead to molecular mimicry situations and could involve the immune system in both positive and negative ways. |
| PL8 | HEALTH EDUCATION OUTREACH ON CONTROL OF HIV INFECTION IN KENYA Int Conf AIDS. 1988 Jun 12-16;4:1.107 (abstract no. PL8) Elizabeth Ngugi The paper highlights the responsibility of individual and groups in prevention of HIV transmission. It traces the educational strategy employed to reach the general population and selected groups at risk in Kenya. The general awareness started in late 1985 and was intensified in 1986-1987. Reduction of sexually transmitted disease is demonstrated. Also stressed is the importance of pre-testing educational material as well as monitoring and evaluation so as to lay the ground for richer health education to combat HIV transmission. The paper concludes by emphasizing developing HIV infection control programme with the people and for the people. |
| PL9 | SEX AND DEATH: THE AIDS CRISIS IN SOCIAL AND CULTURAL CONTEXT Int Conf AIDS. 1988 Jun 12-16;4:1.108 (abstract no. PL9) Sandra Wallman In historical time the AIDS virus is very new. We are only beginning to realise the range of its social impact, and the extent to which the effectiveness of any strategy for controlling it will vary from one cultural setting to another. We now know that the crisis of AIDS is experienced in very different ways in different countries, and by different kinds of people in the same country. In the perspectives of social science these variations are neither random nor accidental. |
| PLENARY SESSION III - Wednesday, June 15 | |
| PL10 | ANTIVIRAL THERAPY Int Conf AIDS. 1988 Jun 12-16;4:1.108 (abstract no. PL10) Bo Öberg An ongoing multiplication of HIV in an infected person seems to be the cause of the development of AIDS. Fortunately, HIV is both a complicated and an increasingly well understood virus and thus offers several good targets for therapy. Targets which have been identified today include the interaction between HIV and T4 receptors, the viral enzymes reverse transcriptase, RNase H, endonuclease, protease, the regulatory proteins tat, sor, art, 3'orf as well as the structural HIV proteins. |
| PL11 | CELL INFECTION BY RETROVIRUSES Int Conf AIDS. 1988 Jun 12-16;4:1.108 (abstract no. PL11) A. Burny1,2, R. Brasseur1, D. Portetelle2, J.M. Ruysschaert1 In the HIV system, it is presumed that the CD4-gp120 complex formation induces a structural change that brings the highly hydrophobic NH -end of gp4l to enter lipid phase of the cell membrane. Important segments of gp120 include the second constant region, a sequence with high homology to neuroleukin-phosphohexose isomerase. Absence of gp120 abrogates the fusion capacity of the remaining particle. |
| PL12 | RECENT DEVELOPMENTS IN THE MANAGEMENT OF AIDS PATIENTS Int Conf AIDS. 1988 Jun 12-16;4:1.108 (abstract no. PL12) Anthony J Pinching Improved management flows from greater understanding of the biology of HIV, better use of existing therapy and new agents for opportunist disease and notably zidovudine. Nutrition and health maintenance together with a positive ethos are crucial. Developments in therapy, maintenance and prophylaxis include: second-line treatment for Pneumocystis and the role of steroids in acute management; inhaled pentamidine and other prophylaxis; improved antifungal therapy; ganciclovir for CMV disease; and new drug regimes for atypical mycobacterial infection and Kaposi's sarcoma. |
| PL13 | HIV INFECTION AMONG PERSONS WHO INJECT ILLICIT DRUGS: PROBLEMS AND PROGRESS Int Conf AIDS. 1988 Jun 12-16;4:1.109(abstract no. PL13) Don C. Des Jarlais We are now into the second decade of HIV infection among persons who inject illicit drugs. This presentation will summarize recent research on the epidemilogy of HIV infection among drug injectors and on efforts to control the spread of the virus within and from the group. The sharing of drug injection equipment with large numbers of other drug injectors has been established as an important factor in HIV spread in both the U.S. and Europe. Membership in an ethnic minority group has also been associated with HIV exposure in a number of American and in one European study, although the mechanism for higher seroprevalence rates among minority groups has not been determined. |
| PL14 | AIDS CARE: MEETING THE HEALTH CARE NEEDS OF THE HIV INFECTED Int Conf AIDS. 1988 Jun 12-16;4:1.109(abstract no. PL14) Constance E. Wofsy In AIDS we have the opportunity to reintroduce the art of healing back into the increasingly technologic practice of medicine. In doing so, we will all face our own mortality. |
| PLENARY SESSION IV - Thursday, June 15 | |
| PL15 | ANIMAL MODELS AND RETROVIRUS VACCINES Int Conf AIDS. 1988 Jun 12-16;4:1.109(abstract no. PL15) R. Kurth, P. Centner, A. Werner, S. Hartung, G. Kraus Practical animal models for AIDS are still lacking but would help significantly to evaluate experimental vaccines and new drugs for their efficacy against HIV. Attempts to develop such animal models for AIDS will be summarized. |
PL16 | PROSPECTS FOR HIV VACCINES Int Conf AIDS. 1988 Jun 12-16;4:1.109(abstract no. PL16) G.L. Ada Four stages in the control of an infectious agent by immunological mechanisms may be postulated. Other proposed approaches (non traditional) will also be discussed. The known situation of responses to other viruses will be used to illustrate particular points. |
| PL17 | SEXUAL CONDUCT AND SEX RESEARCH Int Conf AIDS. 1988 Jun 12-16;4:1.110(abstract no. PL17) John H. Gagnon A number of major sex research intiatives are now being undertaken both nationally and internationally which may give us a more fundamental understanding of sexual development. That these initiatives have been so long in coming suggests the peculiar status of sexuality as a social practice and as the object to scientific research in the modem world. Perhaps it is well to understand that long after the AIDS epidemic is history, sexuality will remain with us as a source of both pleasure and difficulties. |
HETEROSEXUAL TRANSMISSION OF HIV: CURRENT EVIDENCE AND FUTURE PROSPECTS Int Conf AIDS. 1988 Jun 12-16;4:1.110(abstract no. PL18) King K. Holmes Abstract not available. |
| PL19 | A VIROLOGIST'S VIEW OF HIV'S SUCCESSES AND FAILURES Int Conf AIDS. 1988 Jun 12-16;4:1.110(abstract no. PL19) David Baltimore, Sunyoung Kim, Patrick Baeuerle, Mark Muesing, Mark Feinberg The special characteristics of the virus are its lethality, its complex genome structure, its internal regulatory cycles and its regulation by the host cell. These may all be related phenomena and thus are the focus of much attention. By studying the life cycle of HIV, we are trying to define its special properties. We have found a single, critical cellular transcriptional regulatory protein, NF-ocB, that appears important for allowing HIV transcription. |
PL20 | THE ROLE OF SCIENCE Int Conf AIDS. 1988 Jun 12-16;4:1.110(abstract no. PL20) Georg Klein Abstract not available. |
| PLENARY SESSION V AND CLOSING SESSION - Thursday, June 15 | |
| PL21 | THE NEW AIDS VIRUS - INEFFECTIVE AND UNJUST LAWS Int Conf AIDS. 1988 Jun 12-16;4:1.110(abstract no. PL21) The Honourable Justice Michael Kirby CMG Public alarm about the spread of AIDS leads to public demand for drastic laws to contain the epidemic and to punish those who spread it. In this paper, attention is drawn to the limitations of the law in achieving the modification of human behavior. Successes and failures in public health education campaigns, directed to the same end, are mentioned. The author cautions against putting too much trust in the law to achieve containment of the AIDS virus. |
PL22 | CONFRONTING AIDS AT THE NATIONAL LEVEL Int Conf AIDS. 1988 Jun 12-16;4:1.110(abstract no. PL22) Ruhakano Rugunda Abstract not available. |
| PL23 | COOPERATION ACROSS BORDERS Int Conf AIDS. 1988 Jun 12-16;4:1.110(abstract no. PL23) Halfdan Mahler |
| Track A POSTER SESSION 1000 Virology, Abstracts 1001-1202 |
|
| Gene Products | |
| 1001 | STRUCTURAL ANALYSES OF HIV LTRs Int Conf AIDS. 1988 Jun 12-16;4:1.113 (abstract no. 1001) Gerald Myers, C.R. Linder, C.S. Tung At least two of the several critical three-dimensional nucleic acid structures for HIV LTR-directed transactivation can be defined. |
| 1002 | UTILITY OF A HIV 1 RETROVIRAL VECTOR SYSTEM FOR GENE TRANSFER INTO HUMAN CELLS Int Conf AIDS. 1988 Jun 12-16;4:1.113 (abstract no. 1002) V. Heisig, G. Jahn, M. Ebeling, R. Laufs By establishing a helper cell line that produces the trans-acting viral gene products we propagate the cis-acting components in them and harvest defective viral particles that contain only the cis-acting components. In HIV 1 the packaging signal has not been identified. We postulate that the sequence for the packaging signal is located between the primer binding site (PBS) and the gag genes. Therefore we constructed deletion mutants in this region and transfected this mutants into H9 cells. The plasmid pVH3H containing the complete proviral genome of HIV 1 and a hygromycin B gene for selection was used for constructions. An additional deletion in the 3 'LTR (-138 to -48) has been introduced into all plasmids. We have established cell lines with the mutants and studied the reverse transcriptase activity, RNA and protein synthesis. |
| 1003 | THE NINTH CODING SEQUENCE OF HIV-1 Int Conf AIDS. 1988 Jun 12-16;4:1.113 (abstract no. 1003) Zene Matsuda1, Robert Redfield2, Max Essex1, and Tun-Hou Lee1 Our results indicate that in addition to gag, pol, env, sor, tat, art/trs, 3'-orf, and R, HIV-1 contains another coding sequence in its genome. Reactivity to this gene product is indicative of HIV-1, but not HIV-2, infection. |
| 1004 | FUNCTIONAL ANALYSIS OF AN OPEN READING FRAME SPECIFIC TO HIV2/SIV Int Conf AIDS. 1988 Jun 12-16;4:1.113 (abstract no. 1004) M Guyader, K Peden, A Cordonnier, L Chakrabarti, L Montagnier and M Emerman Mutational analysis of an open reading frame specific to HIV2/SIV family may contribute to an under-standing of the differences and similarities between this group of viruses and HIV1. |
| 1005 | AN OPEN READING FRAME UNIQUELY PRESENT IN HIV-2 AND SIV IS A FUNCTIONAL GENE Int Conf AIDS. 1988 Jun 12-16;4:1.114 (abstract no. 1005) Xiao-Fang Yu, Max Essex, and Tun-Hou Lee The open reading frame which is present only in HIV-2 and SIV but not HIV-1 is proven to be a functional gene. |
| 1006 | LOCALIZATION OF P17 EPITOPES BY IMMUNOELECTRON MICROSCOPY IN AND ON HIV-1 Int Conf AIDS. 1988 Jun 12-16;4:1.114 (abstract no. 1006) H Gelderblom1, T Winket1, H Reupke1, JP Rabanus1, M Niedrig1, A Goldstein2, P Sarinx3, G Pauli1 Monospecific polyclonal rabbit and mouse mono–clonal antibodies directed against p17 reacted with epitopes located under the lipid bilayer of virions or budding particles. This immunological finding is substantiated by the direct EM observation of a matrix protein layer underneath the viral membrane. Antibodies produced against a distinct, synthetic fragment of p17 (HPG–30), which shows homology to thymosin, however, labelled in pre–embedding and cryoultramicrotomy IEM determinants on the surface of the virion or budding HIV. |
| 1007 | SYNTHESIS OF EXCRETED 26KDa PROTEINS BY HIV-1 INFECTED CELLS APPARENTLY DIFFERENT FROM THE CORE PROTEIN OF HIV Int Conf AIDS. 1988 Jun 12-16;4:1.114 (abstract no. 1007) AG Laurent, L Montagnier, AG Hovanessian These observations provide evidence for the first time for the synthesis and excretion of 26KDa proteins by HIV-1 infected cells. The function of these 26KDa proteins, their origin (viral or cellular) and their relation to the HIV-1 p25 remain to be elucidated. |
| 1008 | ISOLATION AND CHARACTERIZATION OF HUMAN IMMUNODEFICIENCY VIRUS (HIV-1) GLYCOPROTEINS Int Conf AIDS. 1988 Jun 12-16;4:1.114 (abstract no. 1008) Bharat Parekh and Roger Walker Although gp120 and gp41-43 are not disulfide-linked, a small proportion of gp41-43 may exist as a dimer. The non-reduced form of gp41-43 was found to be more immunoreactive than the reduced molecule. |
| 1009 | PHYSICAL CHARACTERIZATION OF HIV-1 ENVELOPE GLYCOPROTEINS: ENVELOPE PRECURSOR CLEAVAGE OCCURS IN THE RER-GOLGI COMPLEX Int Conf AIDS. 1988 Jun 12-16;4:1.115 (abstract no. 1009) Barry S..Stein1, K Steimer2, EG Engleman1 If mature glycosylated gpl6O is the precursor to gp120 and gp4l, cleavage must occur in the Golgi as gp120 independently undergoes extensive sialylation which is unlikely to be facilitated at the plasma membrane. Alternatively, cleavage of immature gp160 could occur as it traverses the RER. These data reveal gp120 is a hybrid N-linked glycoprotein. |
| 1010 | EXPRESSION AND SELECTION OF GAG GENE RECOMBINANTS FROM THE HIVRF CLONE IN ESCHERICHIA COLI USING A λ EXPRESSION SYSTEM Int Conf AIDS. 1988 Jun 12-16;4:1.115 (abstract no. 1010) Sylvia Crush-Stanton, Bonnie Swerdlow and Michael L. Berman Recombinant clones were screened for expression of antigenic determinants with a pool of several patients' serum. Individual clones were subsequently characterized with anti-p24 mouse monoclonal antibodies. The recombinant proteins express different epitopes as defined by monoclonal antibodies allowing mapping of the antigenic determinants. |
| 1011 | CHARACTERIZATION) OF HIV-2 GLYCOPROTEINS IDENTIFICATION OF AN UNUSUAL HIGH MOLECULAR WEIGHT PRECURSOR OF THE ENVELOPE GLYCOPROTEIN Int Conf AIDS. 1988 Jun 12-16;4:1.115 (abstract no. 1011) MA Rey, B Krust, L Montagnier, AG Hovanessian Four glycoproteins of apparent molecular weights 300,000, 140,000 , 125,000 and 36,000 (gp300, gp140, gp125 and gp36) are detectable in HIV-2 infected T4-antigen positive cells. The gp125 and gp36 are the external and transmembrane components of the envelope glycoproteins of HIV-2 mature virions. The gp300 and gpl40 are only detectable in virus-infected cells. |
| 1012 | EXPRESSION OF p17 HIV PROTEIN IN YEAST Int Conf AIDS. 1988 Jun 12-16;4:1.115 (abstract no. 1012) Teresa CABEZON1, Tineke RUTGERS1, Martine DESCURIEUX1, Jacqueline COGNIAUX2, Ralph BIEMANS1 and Michel DE WILDE1 Yeast shuttle vectors harboring the nucleotide sequences coding for the p17 mature HIV protein or for a fusion p17-p24 protein were constructed and used to transform yeast strains. The yeast cells transformed with those plasmids express p17 related proteins that immunoreact with specific antibodies and with HIV positive human sera. |
| 1013 | CLONING AND EXPRESSION OF RETROVIRAL POL GENES IN BACTERIAL CELLS OF E.COLI Int Conf AIDS. 1988 Jun 12-16;4:1.116 (abstract no. 1013) Melnikov A.A., Kopylova-Sviridova T.N. Tchernov A.P., Fodor I. Pol gene of mammalian retroviruses codes for a large polypeptide precursor of reverse transcriptase (RT) containing domains of protease, RNase H, reverse transcriptase itself and endonuclease activities. The viral protease of avian retroviruses, like Rous sarcoma virus (RSV), is encoded by the gag gene. Detailed characterization of these activities and screening for efficient inhibitors may open new prospects in repression of viral growth and anti-viral therapy. |
| 1014 | ANALYSIS OF THE FUNCTIONS OF THE HIV-1 R AND 3'ORF GENE PRODUCTS Int Conf AIDS. 1988 Jun 12-16;4:1.116 (abstract no. 1014) Lee Ratner and Thomas Niederman HIV-1 is an unusual retrovirus with 8 genes, only 3 of which are known to encode virion proteins. The functions of 2 of its gene products, designated R arid 3'orf have remained obscure. These proteins are predicted to be conserved among different HIV-1 isolates as well as with those of simian immunodeficiency virus and HIV-2. |
| 1015 | FUNCTIONAL ANALYSIS OF THE HIV-1 "A" (SOR) GENE PRODUCT Int Conf AIDS. 1988 Jun 12-16;4:1.116 (abstract no. 1015) Klaus Strehel and Malcolm A. Martin "A" has an important role in the production of infectious virions. Unlike the HIV-1 tat or art gene products, however, the "A" (sor) protein--does not seem to have a function in the regulation of gene expression. Several lines of evidence suggest that "A" acts at the post-translational level and is possibly involved in the modification of some viral proteins. |
| Regulation, General (continued posters 1525-50) | |
| 1016 | SPECIFIC CELL LINES CONTAIN REGULATORY FACTORS WITH HIV TRANSACTIVATOR ACTIVITY Int Conf AIDS. 1988 Jun 12-16;4:1.116 (abstract no. 1016) Howard E. Gendelman, Ronald Willey, Arnold Rabson and Malcolm A. Martin Cellular regulatory factors present in certain cells may substitute for tat. This suggests an indirect action for tat in modifying synthesis of cellular regulatory factors. |
| 1017 | HTLV-II TRANSACTIVATION IS REGULATED BY TWO OVERLAPPING NONSTRUCTURAL GENES Int Conf AIDS. 1988 Jun 12-16;4:1.117 (abstract no. 1017) J.D. Rosenblatt1, W. Wachsman2, A.J. Cann1, D.J. Slamon1, and I.S.Y. Chen1 At low levels of expression rex acts to specifically augment transactivation. When rex mutations are introduced into infectious HTLV-II clones the resultant mutants transcribe very low levels of viral mRNA. However, as much higher rex expression levels are achieved in vitro an unexpected decrease in transactivation is observed, suggesting a possible role in establishing latent infection. These observations have implications for the regulation of other human retroviruses by transacting genes, specifically HIV. |
| 1018 | ANALYSIS OF THE REGULATION OF HIV GENE EXPRESSION USING SV40 BASED EXPRESSION VECTORS Int Conf AIDS. 1988 Jun 12-16;4:1.117 (abstract no. 1018) Marie-Louise Hammarskjöld, Jessica Heimer, David Rekosh The env gene specific probe fails to detect any mRNA in these cells. The deletion mutant expresses a functional tat protein, but does not express detectable amounts of envelope protein unless cotransfected with an art/trs containing vector. Our results indicate that art/trs is important for efficient envelope expression in this heterologous vector system and support the notion that art/trs is involved in the regulation of differential splicing of HIV mRNAs. |
| 1019 | art/trs PROTEIN OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IS ESSENTIAL FOR SPLICING AND/OR TRANSPORT OF HIV TRANSCRIPTS CONTAINING env SEQUENCES Int Conf AIDS. 1988 Jun 12-16;4:1.117 (abstract no. 1019) N. Ahmad, R. J. Mervis, E. P. Lillehoj and S. Venkatesan The above results support the notion that art/trs overcomes the effects of a cis regulatory element inherent in the HIV env sequences that prevents the efficient splicing and/or transport from the nucleus of the transcripts containing these sequences. |
| 1020 | THE SAME INDUCIBLE TRANSCRIPTION FACTOR REGULATES MITOGEN ACTIVATION OF HIV-1 AND THE IL-2 RECEPTOR (TAC) Int Conf AIDS. 1988 Jun 12-16;4:1.117 (abstract no. 1020) E Bohnlein, JW Lowenthal M Siekevitz, BR Franza* and WC Greene A variety of mitogens activate both the HIV-1 LTR and the interleukin-2 receptor (Tac) promoter. Sequences required for mitogen induced IL-2 receptor promoter activation in different T cells have been defined by deletion mutagenesis. The specific interaction of inducible trans-acting factors with these functionally defined sequences has been demonstrated. Using mutated oligonucleotides we have mapped the binding site of one of the factors to a 12 bp segment (-267 to -256). This IL-2 receptor promoter sequence was found to share striking sequence homology with.tne transcriptional enhancer Of the HIV-1 virus. |
| 1021 | SEQUENCE SIMILARITIES BETWEEN HIV-1 AND A PUTATIVE HUMAN LYMPHOCYTE GO/Gl SWITCH GENE Int Conf AIDS. 1988 Jun 12-16;4:1.118 (abstract no. 1021) Donald R. Forsdyke These results suggest that expression of latent HIV-1 might be regulated by factors which recognize sequences common to "latent" host GO/GI regulatory genes and to HIV. The HIV pol. similarity implies that the 3' coding region of the latter gene serves both a coding and a signal-recognition function. This might confer the codon usage bias recently reported by Kypr J & Mrazek J, Nature. 1987 May 7-13;327(6117):20. |
| 1022 | LONG-TERM CLINICAL FOLLOW-UP OF BLOOD DONORS REPEATABLY REACTIVE ON SCREENING EIA BUT WITH NEGATIVE CONFIRMATORY TESTS Int Conf AIDS. 1988 Jun 12-16;4:1.118 (abstract no. 1022) Gillon, J1, and Peutherer, J.F2 Routine screening of blood donors for antibodies to HIV was introduced in October 1985 using the Wellcome assay. Between March and December 1986, 10 donors (7 female, 3 male mean age 31.3 years, range 22-43) had repeatably positive or equivocal results on Wellcome EIA with negative confirmatory tests (different EIA + Western Blot). These donors have been assessed clinically and followed up for mean of 9.6 months (range 7-12 months). There were no relevant clinical abnormalities. None of the donors admitted to membership of high risk groups for HIV |
| 1023 | HIV INFECTION OF T-CELLS PROCEEDS VIA RECEPTOR MEDIATED ENDOCYTOSIS Int Conf AIDS. 1988 Jun 12-16;4:1.118 (abstract no. 1023) David Pauza1, Jose Galindo1, Todd Price2 Accordingly, evidence is presented that infectious entry of HIV into susceptible T-cells proceeds via receptor-mediated endocytosis. In addition, more than 5,000 cell-surface bound virus particles were examined; no evidence was obtained to support the notion that HIV penetration occurs by direct fusion with the plasma membrane. |
| 1024 | ENDOCYTOSIS OF THE HUMAN IMMUNODEFICIENCY VIRUS (HIV-1) Int Conf AIDS. 1988 Jun 12-16;4:1.118 (abstract no. 1024) Pierre G. Bauer1, O.M. Barth2 We suggest that HIV-1, beside direct fusion at the cell surface (Stein et al., Cell. 1987 Jun 5;49(5):659-68, can enter cells by endocytosis, comparable to other enveloped viruses. HIV is taken up by clathrin-coated pits into coated vesicles. These vesicles transport the virus to endosomal vacuoles and multivesicular endosomes (and lysorsomes?), where the hardly detectable fusion of 1 the membranes may occur, probably in a pH-independent way (lit.cit.op.) and mediated by proteins(s) like gp4l, with fusogenic-like peptides] (Gallaher, Cell. 1987 Jul 31;50(3):327-8). |
| 1025 | Int Conf AIDS. 1988 Jun 12-16;4:1.119 (abstract no. 1025) |
| 1026 | Int Conf AIDS. 1988 Jun 12-16;4:1.119 (abstract no. 1026) |
| 1027 | Int Conf AIDS. 1988 Jun 12-16;4:1.119 (abstract no. 1027) |
| 1028 | Int Conf AIDS. 1988 Jun 12-16;4:1.119 (abstract no. 1028) |
| 1029 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1029) |
| 1030 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1030) |
| 1031 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1031) |
| 1032 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1032) |
| 1033 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1033) |
| 1034 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1034) |
| 1035 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1035) |
| 1036 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1036) |
| 1037 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1037) |
| 1038 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1038) |
| 1039 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1039) |
| Structure and function | |
| 1040 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1040) |
| 1041 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1041) |
| 1042 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1042) |
| 1043 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1043) |
| 1044 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1044) |
| 1045 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1045) |
| 1046 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1046) |
| 1047 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1047) |
| Antibody tests (see also session 5500 "Serological tests") | |
| 1048 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1048) |
| 1049 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1049) |
| 1050 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1050) |
| 1051 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1051) |
| 1052 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1052) |
| 1053 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1053) |
| 1054 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1054) |
| 1055 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1055) |
| 1056 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1056) |
| 1057 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1057) |
| 1058 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1058) |
| 1059 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1059) |
| 1060 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1060) |
| 1061 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1061) |
| 1062 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1062) |
| 1063 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1063) |
| 1064 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1064) |
| 1065 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1065) |
| 1066 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1066) |
| 1067 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1067) |
| 1068 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1068) |
| 1069 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1069) |
| 1070 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1070) |
| 1071 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1071) |
| 1072 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1072) |
| 1073 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1073) |
| 1074 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1074) |
| 1075 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1075) |
| 1076 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1076) |
| 1077 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1077) |
| 1078 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1078) |
| 1079 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1079) |
| 1080 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1080) |
| 1081 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1081) |
| 1082 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1082) |
| 1083 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1083) |
| 1084 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1084) |
| False negative and positive antibody results | |
| 1085 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1085) |
| 1086 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1086) |
| 1087 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1087) |
| 1088 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1088) |
| 1089 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1089) |
| 1090 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1090) |
| 1091 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1091) |
| 1092 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1092) |
| 1093 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1093) |
| 1094 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1094) |
| 1095 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1095) |
| Seroconversion and transcient antibody response | |
| 1096 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1096) |
| 1097 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1097) |
| 1098 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1098) |
| 1099 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1099) |
| 1100 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1100) |
| 1101 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1101) |
| 1102 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1102) |
| 1103 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1103) |
| 1104 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1104) |
| Immunoglobulins | |
| 1105 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1105) |
| 1106 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1106) |
| 1107 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1107) |
| 1108 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1108) |
| 1109 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1109) |
| 1110 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1110) |
| 1111 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1111) |
| 1112 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1112) |
| 1113 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1113) |
| Phylogeny | |
| 1114 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1114) |
| 1115 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1115) |
| 1116 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1116) |
| 1117 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1117) |
| 1118 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1118) |
| HTLV-I and other viruses | |
| 1119 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1119) |
| 1120 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1120) |
| 1121 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1121) |
| 1122 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1122) |
| 1123 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1123) |
| 1124 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1124) |
| 1125 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1125) |
| 1126 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1126) |
| 1127 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1127) |
| 1128 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1128) |
| 1129 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1129) |
| 1130 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1130) |
| 1131 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1131) |
| 1132 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1132) |
| 1133 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1133) |
| 1134 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1134) |
| 1135 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1135) |
| 1136 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1136) |
| 1137 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1137) |
| 1138 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1138) |
| Immunoreactive epitopes | |
| 1139 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1139) |
| 1140 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1140) |
| 1141 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1141) |
| 1142 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1142) |
| 1143 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1143) |
| 1144 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1144) |
| 1145 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1145) |
| 1146 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1146) |
| 1147 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1147) |
| 1148 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1148) |
| 1149 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1149) |
| 1150 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1150) |
| 1151 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1151) |
| 1152 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1152) |
| 1153 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1153) |
| 1154 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1154) |
| 1155 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1155) |
| 1156 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1156) |
| 1157 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1157) |
| 1158 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1158) |
| 1159 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1159) |
| 1160 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1160) |
| 1161 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1161) |
| 1162 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1162) |
| 1163 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1163) |
| 1164 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1164) |
| 1165 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1165) |
| 1166 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1166) |
| 1167 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1167) |
| 1168 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1168) |
| 1169 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1169) |
| 1170 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1170) |
| 1171 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1171) |
| 1172 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1172) |
| 1173 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1173) |
| 1174 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1174) |
| 1175 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1175) |
| 1176 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1176) |
| 1177 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1177) |
| 1178 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1178) |
| 1179 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1179) |
| 1180 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1180) |
| 1181 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1181) |
| 1182 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1182) |
| 1183 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1183) |
| 1184 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1184) |
| 1185 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1185) |
| 1186 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1186) |
| 1187 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1187) |
| 1188 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1188) |
| 1189 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1189) |
| 1190 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1190) |
| 1191 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1191) |
| 1192 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1192) |
| 1193 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1193) |
| 1194 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1194) |
| 1195 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1195) |
| 1196 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1196) |
| 1197 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1197) |
| 1198 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1198) |
| 1199 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1199) |
| 1200 | Int Conf AIDS. 1988 Jun 12-16;4:1 (abstract no. 1200) |
| 1201 | HEAT-SHOCK PROTEINS (HSPs) AND HIV INFECTION Int Conf AIDS. 1988 Jun 12-16;4:1.163 (abstract no. 1201) Karamov, E. V., Ulmasov, Kh. A., Rudneva, I. A., Gorchakova, T. A. HIV infected cells apparently use up the main sugar pool for surplus glycosylation of viral glycoproteins, which in turn, cause glucose deficiency and induce GRP-25. |
| 1202 | AIDS CONFIRMATIVE TEST BASED ON RECOMBINANT PROTEINS Int Conf AIDS. 1988 Jun 12-16;4:1.163 (abstract no. 1202) Bukrinsky,M. I., Barsov, E. V., Popov, S. A., Karamov, E. V., Zhdanov, V. M The test can be used as a confirmative one, allowing differential revealing of anticore and antienvelope antibodies. |
| POSTER SESSION 1500 Virology, Abstracts 1501-1701 |
|
| 1501 | Int Conf AIDS. 1988 Jun 12-16;4:2 (abstract no. 1501) |
| 1502 | Int Conf AIDS. 1988 Jun 12-16;4:2 (abstract no. 1502) |
| POSTER SESSION 2000 Pathogenesis/Immunology, Abstracts 2001-2223 |
|
| 2001 | Int Conf AIDS. 1988 Jun 12-16;4:1.164 (abstract no. 2001) |
| 2002 | Int Conf AIDS. 1988 Jun 12-16;4:1.164 (abstract no. 2002) |
| 2003 | Int Conf AIDS. 1988 Jun 12-16;4:1.164 (abstract no. 2003) |
| 2004 | Int Conf AIDS. 1988 Jun 12-16;4:1.164 (abstract no. 2004) |
| 2005 | Int Conf AIDS. 1988 Jun 12-16;4:1.165 (abstract no. 2005) |
| 2006 | Int Conf AIDS. 1988 Jun 12-16;4:1.165 (abstract no. 2006) |
| 2007 | Int Conf AIDS. 1988 Jun 12-16;4:1.165 (abstract no. 2007) |
| 2008 | Int Conf AIDS. 1988 Jun 12-16;4:1.165 (abstract no. 2008) |
| 2009 | Int Conf AIDS. 1988 Jun 12-16;4:1.166 (abstract no. 2009) |
| 2010 | Int Conf AIDS. 1988 Jun 12-16;4:1.166 (abstract no. 2010) |
| 2011 | Int Conf AIDS. 1988 Jun 12-16;4:1.166 (abstract no. 2011) |
| 2012 | Int Conf AIDS. 1988 Jun 12-16;4:1.166 (abstract no. 2012) |
| 2013 | Int Conf AIDS. 1988 Jun 12-16;4:1.167 (abstract no. 2013) |
| 2014 | Int Conf AIDS. 1988 Jun 12-16;4:1.167 (abstract no. 2014) |
| 2015 | Int Conf AIDS. 1988 Jun 12-16;4:1.167 (abstract no. 2015) |
| 2016 | Int Conf AIDS. 1988 Jun 12-16;4:1.167 (abstract no. 2016) |
| 2017 | Int Conf AIDS. 1988 Jun 12-16;4:1.168 (abstract no. 2017) |
| 2018 | Int Conf AIDS. 1988 Jun 12-16;4:1.168 (abstract no. 2018) |
| 2019 | Int Conf AIDS. 1988 Jun 12-16;4:1.168 (abstract no. 2019) |
| 2020 | Int Conf AIDS. 1988 Jun 12-16;4:1.168 (abstract no. 2020) |
| 2021 | Int Conf AIDS. 1988 Jun 12-16;4:1.169 (abstract no. 2021) |
| 2022 | Int Conf AIDS. 1988 Jun 12-16;4:1.169 (abstract no. 2022) |
| 2023 | Int Conf AIDS. 1988 Jun 12-16;4:1.169 (abstract no. 2023) |
| 2024 | Int Conf AIDS. 1988 Jun 12-16;4:1.169 (abstract no. 2024) |
| 2025 | Int Conf AIDS. 1988 Jun 12-16;4:1.170 (abstract no. 2025) |
| 2026 | Int Conf AIDS. 1988 Jun 12-16;4:1.170 (abstract no. 2026) |
| 2027 | Int Conf AIDS. 1988 Jun 12-16;4:1.170 (abstract no. 2027) |
| 2028 | Int Conf AIDS. 1988 Jun 12-16;4:1.170 (abstract no. 2028) |
| 2029 | Int Conf AIDS. 1988 Jun 12-16;4:1.171 (abstract no. 2029) |
| 2030 | Int Conf AIDS. 1988 Jun 12-16;4:1.171 (abstract no. 2030) |
| 2031 | Int Conf AIDS. 1988 Jun 12-16;4:1.171 (abstract no. 2031) |
| 2032 | Int Conf AIDS. 1988 Jun 12-16;4:1.171 (abstract no. 2032) |
| 2033 | Int Conf AIDS. 1988 Jun 12-16;4:1.172 (abstract no. 2033) |
| 2034 | Int Conf AIDS. 1988 Jun 12-16;4:1.172 (abstract no. 2034) |
| 2035 | Int Conf AIDS. 1988 Jun 12-16;4:1.172 (abstract no. 2035) |
| 2036 | Int Conf AIDS. 1988 Jun 12-16;4:1.172 (abstract no. 2036) |
| 2037 | Int Conf AIDS. 1988 Jun 12-16;4:1.173 (abstract no. 2037) |
| 2038 | Int Conf AIDS. 1988 Jun 12-16;4:1.173 (abstract no. 2038) |
| 2039 | Int Conf AIDS. 1988 Jun 12-16;4:1.173 (abstract no. 2039) |
| 2040 | Int Conf AIDS. 1988 Jun 12-16;4:1.173 (abstract no. 2040) |
| 2041 | Int Conf AIDS. 1988 Jun 12-16;4:1.174 (abstract no. 2041) |
| 2042 | Int Conf AIDS. 1988 Jun 12-16;4:1.174 (abstract no. 2042) |
| 2043 | Int Conf AIDS. 1988 Jun 12-16;4:1.174 (abstract no. 2043) |